Title:
ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO GPRC5D AND CD3 AND MEDICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/174238
Kind Code:
A1
Abstract:
Provided are an antigen-binding molecule specifically binding to GPRC5D and CD3, and the medical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.
Inventors:
SHI JINPING (CN)
ZHU MANMAN (CN)
YE CHAOBAIHUI (CN)
YANG XIAOYING (CN)
JIN XINSHENG (CN)
YING HUA (CN)
TAO WEIKANG (CN)
ZHU MANMAN (CN)
YE CHAOBAIHUI (CN)
YANG XIAOYING (CN)
JIN XINSHENG (CN)
YING HUA (CN)
TAO WEIKANG (CN)
Application Number:
PCT/CN2023/081237
Publication Date:
September 21, 2023
Filing Date:
March 14, 2023
Export Citation:
Assignee:
JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/28; A61K39/395
Domestic Patent References:
| WO2018147245A1 | 2018-08-16 | |||
| WO2020114478A1 | 2020-06-11 | |||
| WO2021139758A1 | 2021-07-15 |
Foreign References:
| CN109715667A | 2019-05-03 | |||
| CN114174338A | 2022-03-11 |
Other References:
DATABASE Protein 1 December 2020 (2020-12-01), ANONYMOUS: "Chain O, Obscurin", XP093091859, retrieved from NCBI Database accession no. 4C4K_O
DATABASE Protein 1 December 2020 (2020-12-01), ANONYMOUS: "Chain T, Titin", XP093091861, retrieved from NCBI Database accession no. 2WP3_T
HOSNY MASHHOUR, VERKLEIJ CHRISTIE P. M., VAN DER SCHANS JORT, FRERICHS KRISTINE A., MUTIS TUNA, ZWEEGMAN SONJA, VAN DE DONK NIELS : "Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma", JOURNAL OF CLINICAL MEDICINE, vol. 10, no. 19, 6 October 2021 (2021-10-06), pages 4593, XP093091874, DOI: 10.3390/jcm10194593
MANCIA STEFANIA STEFANIA, FARRELL ANNAMARIA, LOUW KAREN, FLORENDO ERIKA, ARONSON ELIZABETH, PURCELL KIAH, CATAMERO DONNA D, ESCALO: "Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 138, no. Supplement 1, 5 November 2021 (2021-11-05), US , pages 1658 - 1658, XP093091876, ISSN: 0006-4971, DOI: 10.1182/blood-2021-153817
KODAMA, T. ET AL.: "Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma", MOLECULAR CANCER THERAPEUTICS, vol. 18, no. 9, 30 September 2019 (2019-09-30), XP055743011, DOI: 10.1158/1535-7163.MCT-18-1216
DATABASE Protein 1 December 2020 (2020-12-01), ANONYMOUS: "Chain T, Titin", XP093091861, retrieved from NCBI Database accession no. 2WP3_T
HOSNY MASHHOUR, VERKLEIJ CHRISTIE P. M., VAN DER SCHANS JORT, FRERICHS KRISTINE A., MUTIS TUNA, ZWEEGMAN SONJA, VAN DE DONK NIELS : "Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma", JOURNAL OF CLINICAL MEDICINE, vol. 10, no. 19, 6 October 2021 (2021-10-06), pages 4593, XP093091874, DOI: 10.3390/jcm10194593
MANCIA STEFANIA STEFANIA, FARRELL ANNAMARIA, LOUW KAREN, FLORENDO ERIKA, ARONSON ELIZABETH, PURCELL KIAH, CATAMERO DONNA D, ESCALO: "Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 138, no. Supplement 1, 5 November 2021 (2021-11-05), US , pages 1658 - 1658, XP093091876, ISSN: 0006-4971, DOI: 10.1182/blood-2021-153817
KODAMA, T. ET AL.: "Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma", MOLECULAR CANCER THERAPEUTICS, vol. 18, no. 9, 30 September 2019 (2019-09-30), XP055743011, DOI: 10.1158/1535-7163.MCT-18-1216
Attorney, Agent or Firm:
GE CHENG & CO., LTD. et al. (CN)
Download PDF: